[go: up one dir, main page]

MX340714B - Inhibidores de hsp90. - Google Patents

Inhibidores de hsp90.

Info

Publication number
MX340714B
MX340714B MX2012004089A MX2012004089A MX340714B MX 340714 B MX340714 B MX 340714B MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 340714 B MX340714 B MX 340714B
Authority
MX
Mexico
Prior art keywords
purine derivatives
derivatives useful
hsp90 inhibitors
hsp90
inhibitors
Prior art date
Application number
MX2012004089A
Other languages
English (en)
Other versions
MX2012004089A (es
Inventor
Chiosis Gabriela
Taldone Tony
Sun Weilin
Original Assignee
Sloan-Kettering Inst For Cancer Res *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan-Kettering Inst For Cancer Res * filed Critical Sloan-Kettering Inst For Cancer Res *
Publication of MX2012004089A publication Critical patent/MX2012004089A/es
Publication of MX340714B publication Critical patent/MX340714B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud proporciona los derivados de purina sustituidos y los compuestos relacionados de las fórmulas mostradas. Estos compuestos son útiles como inhibidores de HSP90, y por lo tanto, en el tratamiento de las enfermedades relacionadas. (Fórmulas) Z1-Z3, Xa-XC, X2, X4, Y y R son según lo definido en la especificación.
MX2012004089A 2009-10-07 2010-10-07 Inhibidores de hsp90. MX340714B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24934909P 2009-10-07 2009-10-07
PCT/US2010/051872 WO2011044394A1 (en) 2009-10-07 2010-10-07 Purine derivatives useful as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
MX2012004089A MX2012004089A (es) 2012-08-23
MX340714B true MX340714B (es) 2016-07-22

Family

ID=43857159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004089A MX340714B (es) 2009-10-07 2010-10-07 Inhibidores de hsp90.

Country Status (16)

Country Link
US (2) US9328114B2 (es)
EP (2) EP2486039B1 (es)
JP (3) JP5941407B2 (es)
KR (2) KR102129420B1 (es)
CN (3) CN105924443A (es)
AU (1) AU2010303343B2 (es)
BR (1) BR112012008019A2 (es)
CA (1) CA2776308C (es)
DK (1) DK2486039T3 (es)
EA (1) EA029272B1 (es)
ES (2) ES2589403T3 (es)
LT (1) LT2486039T (es)
MX (1) MX340714B (es)
NZ (2) NZ625593A (es)
PT (1) PT2486039T (es)
WO (1) WO2011044394A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2008005937A2 (en) * 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
CN105924443A (zh) 2009-10-07 2016-09-07 斯隆-凯特林癌症研究院 用作Hsp90抑制剂的嘌呤衍生物
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
WO2013009657A1 (en) 2011-07-08 2013-01-17 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
CN111285813A (zh) 2013-08-23 2020-06-16 润新生物公司 化学实体、组合物和方法
BR112016014758A8 (pt) 2013-12-23 2020-06-02 Memorial Sloan Kettering Cancer Center composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto
CA2961499A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
AU2016336351A1 (en) 2015-10-05 2018-05-10 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
EP4006035B1 (en) 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
EP3615008A4 (en) * 2017-04-24 2021-05-05 Samus Therapeutics, Inc. ORAL HSP90 INHIBITOR FORMULATIONS AND RELATED PROCESSES
CA3068274A1 (en) * 2017-06-23 2018-12-27 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841549D1 (de) 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
CA2370007A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
CA2426952C (en) 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
JP4397691B2 (ja) * 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
NL1019258C2 (nl) * 2001-10-30 2003-05-02 Iku Holding Montfoort Bv Bevestigingsconstructie, in het bijzonder voor een buitenspiegel van een motorvoertuig.
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
AU2003207340A1 (en) 2002-02-28 2003-09-09 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
EP1620564A4 (en) 2003-04-18 2008-03-12 Cytovia Inc METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
WO2007014361A2 (en) 2005-07-27 2007-02-01 Qualcomm Incorporated System and method for a forward link only protocol suite
CN101490052B (zh) * 2006-05-12 2012-08-08 美瑞德生物工程公司 治疗性化合物及其在癌症中的用途
WO2007143629A1 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
US20080053862A1 (en) 2006-06-30 2008-03-06 Sanford, L.P. Interlocking Nestable Article Holder
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
RS52978B (en) 2007-03-20 2014-02-28 Curis, Inc. FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
WO2009007399A1 (en) 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CA2705579A1 (en) 2007-11-14 2009-05-22 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in treating diseases and disorders
CN105924443A (zh) 2009-10-07 2016-09-07 斯隆-凯特林癌症研究院 用作Hsp90抑制剂的嘌呤衍生物
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения

Also Published As

Publication number Publication date
CN106083855A (zh) 2016-11-09
AU2010303343A1 (en) 2012-04-19
US9328114B2 (en) 2016-05-03
LT2486039T (lt) 2016-10-10
EA201270535A1 (ru) 2012-09-28
BR112012008019A2 (pt) 2016-03-01
JP2018104451A (ja) 2018-07-05
NZ599138A (en) 2014-06-27
KR102129420B1 (ko) 2020-07-03
PT2486039T (pt) 2016-09-06
JP5941407B2 (ja) 2016-06-29
EP2486039A1 (en) 2012-08-15
KR20180112117A (ko) 2018-10-11
EP2486039B1 (en) 2016-06-01
ES2589403T3 (es) 2016-11-14
EA029272B1 (ru) 2018-03-30
EP3091019B1 (en) 2019-04-03
ES2733131T3 (es) 2019-11-27
EP2486039A4 (en) 2012-08-15
KR101906568B1 (ko) 2018-10-10
AU2010303343B2 (en) 2015-11-19
CA2776308A1 (en) 2011-04-14
US20160310497A1 (en) 2016-10-27
CA2776308C (en) 2020-01-28
US10172863B2 (en) 2019-01-08
CN106083855B (zh) 2020-04-10
JP6326088B2 (ja) 2018-05-16
JP2016145262A (ja) 2016-08-12
KR20120083898A (ko) 2012-07-26
US20120208806A1 (en) 2012-08-16
CN102639534A (zh) 2012-08-15
CN105924443A (zh) 2016-09-07
DK2486039T3 (en) 2016-09-12
EP3091019A3 (en) 2017-01-18
JP2013507381A (ja) 2013-03-04
JP6804483B2 (ja) 2020-12-23
NZ625593A (en) 2016-03-31
WO2011044394A1 (en) 2011-04-14
EP3091019A2 (en) 2016-11-09
MX2012004089A (es) 2012-08-23

Similar Documents

Publication Publication Date Title
MX340714B (es) Inhibidores de hsp90.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
MX2019010602A (es) Inhibidores de cdk.
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2009010595A (es) Derivados de pirrolopirimidina.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2008001538A (es) Aril piridinas y metodos para su uso.
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MX2009013077A (es) Derivados dde benzoxazolona.
WO2010003475A8 (de) Neue pyrrolidinderivate als metap-2 inhibitoren
NZ589844A (en) Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IN2012DN03182A (es)
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.

Legal Events

Date Code Title Description
FG Grant or registration